Hilary Gee Goeckner, Director State & Local Campaigns at American Cancer Society Cancer Action Network, discusses the significant importance of recent state biomarker legislation and its ability to dramatically expand coverage for advanced diagnostics in the United States. Key topics discuss include the history of cancer biomarker legislation and reasons for Cancer Action Network’s advocacy, details of legislation being enacted at numerous states, mandates of coverage for evidence-based tests and key qualifying criteria including FDA approval, national coverage determinations, local coverage determination, and professional guidelines, whether laws are specific to cancer or cover other biomarker based tests, variation in legislation across states, reasons for general bipartisan support, states where enacted and timelines to become effective, potential areas of commercial payer/State Medicaid pushback, impact on prior-authorizations, potential for reimbursement for lower quality diagnostic tests.